LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Innoviva Inc

Cerrado

SectorSalud

20.17 -1.22

Resumen

Variación precio

24h

Actual

Mínimo

20.05

Máximo

20.37

Métricas clave

By Trading Economics

Ingresos

110M

64M

Ventas

12M

100M

P/B

Media del Sector

35.895

35.733

Margen de beneficio

63.508

Empleados

127

EBITDA

111M

84M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+96.73% upside

Dividendos

By Dow Jones

Próximas Ganancias

4 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

124M

1.3B

Apertura anterior

21.39

Cierre anterior

20.17

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

74 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Innoviva Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

9 sept 2025, 23:37 UTC

Acciones populares

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 sept 2025, 20:41 UTC

Ganancias

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 sept 2025, 20:30 UTC

Ganancias

GameStop 2Q Sales, Profit Rise

9 sept 2025, 23:19 UTC

Charlas de Mercado

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 sept 2025, 21:35 UTC

Ganancias

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 21:32 UTC

Ganancias

Oracle's Backlog Swells With Big Customer Deals -- Update

9 sept 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

9 sept 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 sept 2025, 20:26 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:23 UTC

Ganancias

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 sept 2025, 20:12 UTC

Ganancias

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 sept 2025, 20:10 UTC

Ganancias

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 sept 2025, 20:09 UTC

Ganancias

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 sept 2025, 20:08 UTC

Ganancias

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 sept 2025, 20:07 UTC

Ganancias

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Software Revenue $5.72B >ORCL

9 sept 2025, 20:06 UTC

Ganancias

Synopsys 3Q Adj EPS $3.39 >SNPS

9 sept 2025, 20:06 UTC

Ganancias

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Rev $14.93B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q EPS $1.01 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Synopsys 3Q EPS $1.50 >SNPS

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Services Revenue $1.35B >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Adj EPS $1.47 >ORCL

9 sept 2025, 20:05 UTC

Ganancias

Oracle 1Q Hardware Revenue $670M >ORCL

Comparación entre iguales

Cambio de precio

Innoviva Inc Esperado

Precio Objetivo

By TipRanks

96.73% repunte

Estimación a 12 meses

Media 40.25 USD  96.73%

Máximo 55 USD

Mínimo 26 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Innoviva Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

18.57 / 18.75Soporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

74 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat